00

Sunflower Pharmaceutical Group Co LtdSHE 002737 Stock Report

Last reporting period 30 Sep, 2023

Updated 08 Nov, 2024

Last price

Market cap $B

1.696

Small

Exchange

XSHE - Shenzhen Stock Exchange

002737.SZ Stock Analysis

00

Attractive

Based on Eyestock quantitative analysis, 002737.SZ`s fundamental data and valuation indicate an investment grade of Attractive at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

129/100

High score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

41.0 %

Greatly undervalued

Market cap $B

1.696

Dividend yield

5.13 %

Shares outstanding

581.05 B

Sunflower Pharmaceutical Group Co., Ltd. engages in the research and development, manufacturing, and marketing of proprietary Chinese medicines. The company is headquartered in Harbin, Heilongjiang and currently employs 5,636 full-time employees. The company went IPO on 2014-12-30. The firm provides drugs in six categories, including digestive medicine, pediatric medicine, gynecological medicine, rheumatoid bone medication, breathing cold medication and cardiovascular drugs. The Company’s main products include Weikangling capsules, liver tablets, hyperactivity cough oral liquid for children use, pediatric Huatanzhike particles, Kangfu anti-inflammatory suppository and pediatric paracetamol particles, among others. The firm distributes its products in domestic market.

View Section: Eyestock Rating